Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 3.5% vs TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution